Projects funded by the NCN
Development of macrocyclic peptide antagonists of the PD-1/PD-L1 pathway. Charcterization of simultaneous administration of two immunomodulating agents in antitumor response
2018/31/D/NZ7/01900
Keywords:
immunomodulating agents macrocyclic peptides immunocheckpoint
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ6_2: Clinical immunology
- ST5_16:
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Jagielloński, Wydział Chemii
woj. małopolskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 5
Call: SONATA 14 - announced on 2018-09-14
Amount awarded: 1 093 600 PLN
Project start date (Y-m-d): 2019-07-05
Project end date (Y-m-d): 2024-07-04
Project duration:: 36 months (the same as in the proposal)
Project status: Project completed
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (3)
- Human and mouse PD-L1: similar molecular structure, but different druggability profilesAuthors:Katarzyna Magiera-Mularz, Justyna Kocik, Bogdan Musielak, Jacek Plewka, Dominik Sala, Monika Machula, Przemyslaw Grudnik, Malgorzata Hajduk, Marcin Czepiel, Maciej Siedlar, Tad A. Holak, Lukasz SkalniakAcademic press:iScience (rok: 2021, tom: 24, strony: 101960), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.isci.2020.101960 - link to the publication
- Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune CheckpointAuthors:Katarzyna Magiera-Mularz(†), Katarzyna Kuska(†), Lukasz Skalniak, Przemyslaw Grudnik, Bogdan Musielak, Jacek Plewka, Justyna Kocik, Malgorzata Stec, Kazimierz Weglarczyk, Dominik Sala, Benedykt Wladyka, Maciej Siedlar, Tad A. Holak,* and Grzegorz Dubin*Academic press:Advanced Therapeutics (rok: 2021, tom: 4, strony: 2000195), Wydawca: WileyStatus:PublishedDOI:10.1002/adtp.202000195 - link to the publication
- Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodiesAuthors:Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak & Katarzyna Magiera-MularzAcademic press:Molecular Cancer (rok: 2023, tom: 22, strony: 150), Wydawca: BMCStatus:PublishedDOI:10.1186/s12943-023-01853-4 - link to the publication